YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Incidence and Severity of Weight Gain Associated with the Use of Olanzapine for the Treatment of Schizophrenia

올란자핀의 체중증가 부작용 발생율 및 체중변화량

  • Published : 2008.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

Olanzapine, an atypical antipsychotic, has been widely used for the treatment of schizophrenia and bipolar disease. Although olanzapine is less associated with extrapyramidal symptoms and neuroleptic malignant syndrome compared to existing typical antipsychotics, the use of this drug has a problematic side effect of weight gain, which may cause metabolic syndrome such as type 2 diabetes. However, there are few hospitals practicing body weight monitoring of the patients on olanzapine or other atypical antipsychotics. The goal of this study was to identify the incidence and severity of weight gain associated with the use of the drug in Korea. We performed body weight monitoring of the patients who were on the drug in a hospital setting. Mean of the weight gain (as of one-month-transformation) was 4.33 and 3.39 kg for the male and female patients, respectively. The incidence in the young patients was higher than that observed in the old patients, and the severity was the highest in patients in their thirties followed by twenties or younger. This result suggests that the pattern of the weight gain associated with the use of olanzapine in Korea is similar to the reports performed and documented in US and European countries. Therefore, it appears that healthcare professionals in Korea should also watch on the weight gain issue in patients who are on olanzapine or other atypical antipsychotics.

Keywords

References

  1. Lund, B. and Perry, P. : Olanzapine: an atypical antipsychotic for schizophrenia. Expert Opin. Pharmacother. 1, 305 (2000) https://doi.org/10.1517/14656566.1.2.305
  2. Bhana, N., Foster, R., Olney, R. and Plosker, G. : Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 61, 111 (2001) https://doi.org/10.2165/00003495-200161010-00011
  3. Matza, L., Baker, T. and Revicki, D. : Efficacy of olanzapine and ziprasidone for the treatment of schizophrenia: a systematic review. CNS Drugs 19, 499 (2005) https://doi.org/10.2165/00023210-200519060-00003
  4. Yatham, L., Goldstein, J., Vieta, E., Bowden, C., Grunze, H., Post, R., Suppes, T. and Calabrese, J. : Atypical antipsychotics in bipolar depression: potential mechanisms of action. J. Clin. Psychiatry 66(Suppl 5), 40 (2005)
  5. Eli Lilly and Company. $Zyprexa^{TM}$ (olanzapine). http:// pi.lilly.com/us/zyprexa-pi.pdf (accessed on May 9, 2008 May)
  6. McClellan, J. : Olanzapine and pediatric bipolar disorder: evidence for efficacy and safety concerns. Am. J. Psychiatry 164, 1462 (2007) https://doi.org/10.1176/appi.ajp.2007.07071148
  7. Strawn, J. and Delbello, M. : Olanzapine for the treatment of bipolar disorder in children and adolescents. Expert Opin. Pharmacother. 9, 467, (2008) https://doi.org/10.1517/14656566.9.3.467
  8. Ketter, T., Houston, J., Adams, D., Risser, R., Meyers, A., Williamson, D. and Tohen, M. : Differential efficacy of olanzapine and lithium in preventing manic or mixed recurrence in patients with bipolar I disorder based on number of previous manic or mixed episodes. J. Clin. Psychiatry 67, 95, (2006) https://doi.org/10.4088/JCP.v67n0113
  9. Chengappa, K., Pollock, B., Parepally, H., Levine, J., Kirshner, M., Brar, J. and Zoretich, R. : Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine. J. Clin. Psychopharmacol. 20, 311 (2000) https://doi.org/10.1097/00004714-200006000-00004
  10. Mulsant, B., Gharabawi, G., Bossie, C., Mao, L., Martinez, R., Tune, L., Greenspan, A., Bastean, J. and Pollock, B. : Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. J. Clin. Psychiatry 65, 1708 (2004) https://doi.org/10.4088/JCP.v65n1217
  11. Isaac, M. and Isaac, M. : Olanzapine and weight gain. Am. J. Psychiatry 162, 1764 (2005) https://doi.org/10.1176/appi.ajp.162.9.1764
  12. http://lawprofessors.typepad.com/mass_tort_litigation/zyprexa/ index.html (accessed on May 8, 2008)
  13. http://www.symbyax.com/prescribing/consumer_safety.jsp (accessed on May 8, 2008)
  14. Smith, E., Rothschild, A., Heo, M., Peasley-Miklus, C., Caswell, M., Papademetriou, E., Flint, A., Mulsant, B. and Meyers, B. : Weight gain during olanzapine treatment for psychotic depression: effects of dose and age. Int. Clin. Psychopharmacol. 23, 130 (2008) https://doi.org/10.1097/YIC.0b013e3282f424d6
  15. Meyer, J. : A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J. Clin. Psychiatry 63, 425 (2002) https://doi.org/10.4088/JCP.v63n0509
  16. Kinon, B., Kaiser, C., Ahmed, S., Rotelli, M. and Kollack- Walker, S. : Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J. Clin. Psychopharmacol. 25, 255 (2005)
  17. Lipkovich, I., Citrome, L., Perlis, R., Deberdt, W., Houston, J., Ahl, J. and Hardy, T. : Early predictors of substantial weight gain in bipolar patients treated with olanzapine. J. Clin. Psychopharmacol. 26, 316 (2006) https://doi.org/10.1097/01.jcp.0000219916.88810.1c
  18. Fleischhaker, C., Heiser, P., Hennighausen, K., Herpertz- Dahlmann, B., Holtkamp, K., Mehler-Wex, C., Rauh, R., Remschmidt, H., Schulz, E. and Warnke, A. : Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents. J. Neural. Transm. 114, 273 (2007) https://doi.org/10.1007/s00702-006-0602-7